MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Provided By PR Newswire
Last update: Nov 6, 2025
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Non-Titrated Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity; Top-Line Data Expected by Year-End 2025
Read more at prnewswire.com0.7502
+0.04 (+5.16%)
Find more stocks in the Stock Screener
MTVA Latest News and Analysis
